[이코노믹리뷰=황진중 기자] HK Innoen (195940)’s new drug K-Cap for gastroesophageal reflux disease recorded a cumulative outpatient prescription record of 88 billion won from January to October of this year. This figure is well above the 76.1 billion won that was recorded last year. HK Innoen has recently expanded the coverage of K-Cap to include gastric ulcer, and is further strengthening its position as a blockbuster domestic drug by developing a new orally disintegrating tablet.
According to UBIST on the 15th, HK Innoen’s new drug K-Cap for gastroesophageal reflux disease recorded 9.89 billion won in outpatient prescriptions per month in October. Cumulative outpatient prescriptions from January to October of this year amounted to 88 billion won.
After being released as the 30th new drug in Korea in 2019, K-Cap Tablet exceeded 100 billion won in cumulative outpatient prescriptions within two years, raising the status of a blockbuster domestic new drug. Since its launch, the performance achieved with only one K-cap tablet is 195 billion won.
K-Cab Tablet, a new drug of the new series (P-CAB), has the advantage of showing the drug effect faster than the existing PPI series products, that it can be taken regardless of before or after a meal, and that it suppresses gastric acid secretion during the night with excellent drug efficacy. have.
HK Innoen, which is changing the flow of the gastroesophageal reflux disease treatment market, recently applied to the Ministry of Food and Drug Safety for permission for an orally disintegrating tablet following the K-cap tablet (pill). Orally disintegrating tablets, which dissolve in the mouth, are mainly used for patients who have difficulty swallowing tablets or unable to drink water. HK Innoen expects that the scope of entry will be further expanded when the K-cap orally disintegrating tablet is released in earnest in the first half of next year.
Kang Seok-hee, CEO of HK Innoen, said, “K-cap tablets will be active in overseas markets such as China from next year. said
K-Cap Tablet currently has a total of 4 indications (range of use) in Korea, including antibiotic combination therapy for erosive gastroesophageal reflux disease, non-erosive gastroesophageal reflux disease, gastric ulcer and Helicobacter pylori eradication. Among them, the scope of health insurance coverage has been expanded to include erosive and non-erosive gastroesophageal reflux disease and recently gastric ulcer.
HK Innoen is conducting domestic clinical trials such as maintenance therapy (Phase 3) after gastroesophageal reflux disease treatment, and nonsteroidal anti-inflammatory and analgesic (NSAIDs)-induced gastric and duodenal ulcer prevention therapy (Phase 3). ) is steadily increasing.
.
